BioCentury
ARTICLE | Company News

Amrad Development Pty Ltd., Collateral, Ludwig Institute for Cancer Research deal

September 8, 1998 7:00 AM UTC

CLTX terminated its 1997 licensing agreement with the other parties for the use of the VEGF-B gene ( vascular endothelial growth factor B) in therapies for myocardial ischemia (see BioCentury, April ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article